A carregar...
No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
BACKGROUND & AIMS: It is unclear if there are differences between direct-acting antivirals (DAAs) for hepatitis C virus (HCV) in risk of hepatocellular carcinoma (HCC) after antiviral therapy. We aimed to compare different DAA regimens with respect to risk of de novo HCC following antiviral ther...
Na minha lista:
| Publicado no: | Eur J Gastroenterol Hepatol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279503/ https://ncbi.nlm.nih.gov/pubmed/30142097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MEG.0000000000001242 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|